Drug Profile
Research programme: zinc trisodium pentetate oral - National Resilience
Alternative Names: NanoDTPA™; NanoDTPA™Zn-DTPALatest Information Update: 18 Jun 2021
Price :
$50
*
At a glance
- Originator Nanotherapeutics
- Developer National Institute of Allergy and Infectious Diseases; National Resilience
- Class Acetic acids; Heavy metals; Small molecules
- Mechanism of Action Chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute radiation syndrome
Most Recent Events
- 02 Oct 2017 Nanotherapeutics is now called Ology Bioservices
- 16 Jul 2016 No recent reports of development identified for preclinical development in Acute-radiation-syndrome in USA (PO, Capsule)
- 31 Aug 2010 Nanotherapeutics files an IND application with the US FDA for the treatment of Acute radiation syndrome with zinc trisodium pentetate oral